Search results for "protein"

showing 10 items of 21431 documents

Role of biomarkers in the management of antibiotic therapy : an expert panel review : I - currently available biomarkers for clinical use in acute in…

2013

Abstract In the context of worldwide increasing antimicrobial resistance, good antimicrobial prescribing in more needed than ever; unfortunately, information available to clinicians often are insufficient to rely on. Biomarkers might provide help for decision-making and improve antibiotic management. The purpose of this expert panel review was to examine currently available literature on the potential role of biomarkers to improve antimicrobial prescribing, by answering three questions: 1) Which are the biomarkers available for this purpose?; 2) What is their potential role in the initiation of antibiotic therapy?; and 3) What is their role in the decision to stop antibiotic therapy? To ans…

medicine.medical_specialtymedicine.drug_class[SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]AntibioticsMEDLINEContext (language use)ReviewCritical Care and Intensive Care MedicineProcalcitoninC-reactive proteinsuPARsepsis03 medical and health sciences0302 clinical medicineAntibiotic resistanceemergency medicineAntibiotic therapy[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]Medicine030212 general & internal medicineIntensive care medicine030304 developmental biologyddc:6160303 health sciencessepticemie[ SDV.MHEP.PHY ] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]business.industryPresepsin[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieproADMsTREM-1infection3. Good healthSanté publique et épidémiologie[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieBiomarker (medicine)infection;sepsis;emergency medicine;biomarker;procalcitonin;C-reactive protein;sTREM-1;suPAR;proADM;resepsinbiomarker[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieresepsinbusinessbiomarqueurBiomarkersprocalcitonin
researchProduct

Papel de la antitrombina iii en cirugía cardiaca

2013

Coagulation of blood is of multidisciplinary interest. Cardiac surgery produces major changes in the delicate balance between pro-and anti-coagulant serum factors. The role of antithrombin iii has been analysed after finding evidence that associated decreased levels of protein activity to postoperative morbidity and mortality. Supplementing exogenous antithrombin is considered with the aim of optimising outcomes. Its intrinsic anticoagulant and anti-inflammatory properties have stimulated a growing interest, and suggests new lines of research.

medicine.medical_specialtymedicine.drug_classbusiness.industryAnticoagulantAntithrombinCritical Care and Intensive Care MedicineCardiac surgeryAnesthesiology and Pain MedicineCoagulationInternal medicinemedicineCardiologyProtein activitybusinessmedicine.drugRevista Española de Anestesiología y Reanimación
researchProduct

The search for novel avenues for the therapy and prevention of Alzheimer's disease.

2006

The prevention and therapy of neurodegenerative disorders in the elderly is one of the greatest challenges facing molecular medicine today. Alzheimer's is an excellent example of a disease being studied by many groups worldwide. Indeed, while many molecular details of this disorder have been elucidated in the last two decades, there are still no strictly causal therapies available. While certain symptomatic pharmacological treatments are frequently employed, current molecular medicine research is focused on central Alzheimer-associated biochemical changes to find the key switch that turns the detrimental Alzheimer process on. Although amyloid beta proteins and tau proteins are the focus of …

medicine.medical_specialtymedicine.drug_classbusiness.industryFemale sexDiseaseBioinformaticsMolecular medicineEndocrinologyAmyloid beta proteinsEstrogenGSK-3Alzheimer DiseaseInternal medicinemedicineAnimalsHumansNeuroprotective factorsbusinessHormoneDrug newsperspectives
researchProduct

Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons

2009

Metabotropic glutamate (mGlu) receptors have been considered potential targets for the therapy of experimental parkinsonism. One hypothetical advantage associated with the use of mGlu receptor ligands is the lack of the adverse effects typically induced by ionotropic glutamate receptor antagonists, such as sedation, ataxia, and severe learning impairment. Low doses of the mGlu2/3 metabotropic glutamate receptor agonist, LY379268 (0.25-3 mg/kg, i.p.) increased glial cell line-derived neurotrophic factor (GDNF) mRNA and protein levels in the mouse brain, as assessed by in situ hybridization, real-time PCR, immunoblotting, and immunohistochemistry. This increase was prominent in the striatum, …

medicine.medical_specialtymedicine.drug_classlcsh:MedicineSubstantia nigraReceptors Metabotropic GlutamateSettore BIO/09 - FisiologiaPolymerase Chain ReactionMiceNeurotrophic factorsInternal medicinemedicineGlial cell line-derived neurotrophic factorAnimalsGlial Cell Line-Derived Neurotrophic FactorRNA MessengerAmino Acidslcsh:ScienceReceptorIn Situ HybridizationNeurological Disorders/Movement DisordersNeuronsMultidisciplinarybiologyNeuroscience/Neuronal and Glial Cell Biologylcsh:RGlutamate receptorBridged Bicyclo Compounds HeterocyclicReceptor antagonistCorpus StriatumEndocrinologyMetabotropic receptornervous systemMetabotropic glutamate receptorSettore BIO/14 - Farmacologiabiology.proteinlcsh:QNeuroscience/Neurobiology of Disease and RegenerationReceptors Metabotropic Glutamate/agonists Glial Cell Line-Derived Neurotrophic FactorResearch Article
researchProduct

Antihistamine-resistant Angioedema in Women with Negative Family History: Estrogens and F12 Gene Mutations

2013

Abstract Background In women with sporadic recurrent angioedema with an unknown cause who are unresponsive to antihistamines and have normal C1 inhibitor activity and a negative family history of angioedema, it is unclear whether they have idiopathic angioedema or hereditary angioedema with normal C1 inhibitor, and what impact exogenous estrogens have on their angioedema. Methods A cohort of 147 women was analyzed for F12 exon 9 mutations and for the influence of oral contraceptives, hormonal replacement therapy, and pregnancy on their angioedema. Results A total of 142 women had idiopathic angioedema unresponsive to antihistamines. Five women had an F12 mutation and thereby hereditary angi…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentGene mutationC1-inhibitorimmune system diseasesInternal medicinemedicineHereditary Angioedema Type IIIcardiovascular diseasesFamily historyskin and connective tissue diseasesbiologyAngioedemabusiness.industryfood and beveragesGeneral Medicinemedicine.diseaseDermatologyEndocrinologyEstrogenHereditary angioedemabiology.proteinAntihistaminemedicine.symptombusinessThe American Journal of Medicine
researchProduct

FLT3 as a therapeutic target in AML: still challenging after all these years

2010

Abstract Mutations within the FMS-like tyrosine kinase 3 (FLT3) gene on chromosome 13q12 have been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of the most frequently identified genetic alterations in AML. Over the last years, FLT3 has emerged as a promising molecular target in therapy of AML. Here, we review results of clinical trials and of correlative laboratory studies using small molecule FLT3 tyrosine kinase inhibitors (TKIs) in AML patients. We also review mechanisms of primary and secondary drug resistance to FLT3-TKI, and from the data currently available we summarize lessons learned from FLT3-TKI monotherapy. Finally, for using FLT3 as a molecul…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentImmunologyBiologyBiochemistryTyrosine-kinase inhibitorTargeted therapychemistry.chemical_compoundfluids and secretionshemic and lymphatic diseasesInternal medicinemedicineHumansProtein Kinase InhibitorsQuizartinibHematologyMyeloid leukemiaCancerhemic and immune systemsCell BiologyHematologymedicine.diseaseLeukemia Myeloid Acutefms-Like Tyrosine Kinase 3chemistryDrug Resistance Neoplasmembryonic structuresCancer researchTyrosine kinaseCrenolanibBlood
researchProduct

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

2018

Abstract Background Prediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain. Objective To assess the influence of rivaroxaban and apixaban on several coagulation factor levels. Methods In two crossover trials we assessed the influence of rivaroxaban and apixaban intake on factor (F)VIII, FXI and FXII‐activity and fibrinogen, von Willebrand factor (VWF:Ag), and d‐dimer levels. At three sessions with a washout period in between, blood was taken from 12 healthy male individu…

medicine.medical_specialtymedicine.drug_mechanism_of_actionFactor Xa Inhibitorapixabanfactor Xa inhibitors030204 cardiovascular system & hematologyTreatment resultsFibrinogenGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorInternal medicinecoagulantsMedicinerivaroxabanBlood coagulation testRivaroxabanbiologybusiness.industryBrief Reportblood coagulation testsrisk assessmentHematologyCoagulation030220 oncology & carcinogenesisbiology.proteinApixabanbusinessOriginal Articles: Thrombosismedicine.drug
researchProduct

Cigarette smoke-induced pulmonary endothelial dysfunction is partially suppressed by sildenafil.

2009

Abstract Cigarette smoke mediated oxidative stress and endothelial dysfunction are important processes in the pathogenesis of several lung disorders. In this study we evaluated the effect of PDE5 inhibition on pulmonary artery endothelial dysfunction induced by cigarette smoke in vitro . Human pulmonary artery endothelial cells (HPAEC) were incubated in the absence or presence of PDE5 inhibitor sildenafil (10 nM–1 μM), PKG agonist 8-Br-cGMP (1 mM), or the antioxidants dyphenyleneiodonium (DPI 1 μM) and N -acetylcysteine (NAC 1 mM) for 30 min. Then, cigarette smoke extract (CSE) was added for 24 h. CSE (2.5–10%)-induced ROS generation was suppressed by DPI, and partially reversed by sildenaf…

medicine.medical_specialtymedicine.drug_mechanism_of_actionSildenafilVasodilator AgentsPharmaceutical ScienceEnzyme-Linked Immunosorbent Assaymedicine.disease_causeNitric OxidePolymerase Chain ReactionPiperazinesSildenafil CitrateAcetylcysteinechemistry.chemical_compoundInternal medicineSmokeparasitic diseasesTobaccomedicineHumansSulfonesEndothelial dysfunctionPhosphodiesterase inhibitorLungCells CulturedDNA PrimersbiologyBase Sequencebusiness.industrymedicine.diseaseEndothelial stem cellEndocrinologychemistryEnzyme inhibitorPurinescardiovascular systembiology.proteinEndothelium VascularbusinessPhosphodiesterase 5 inhibitorOxidative stressmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Type 1 or Type 2 Myocardial Infarction in Patients with a History of Coronary Artery Disease: Data from the Emergency Department

2019

A type 2 myocardial infarction (T2MI) is the result of an imbalance between oxygen supply and demand, without acute atherothrombosis. T2MI is frequent in emergency departments (ED), but has not been extensively evaluated in patients with previously known coronary artery disease (CAD). Our study assessed the incidence and characteristics of T2MI compared to type 1 (T1MI) in CAD patients admitted to an ED. Among 33,669 consecutive patients admitted to the ED, 2830 patients with T1MI or T2MI were systematically included after prospective adjudication by the attending clinician according to the universal definition. Among them, 619 (22%) patients had a history of CAD. Using multivariable analys…

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyArticletype 2 myocardial infarctionCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicinemedicine030212 general & internal medicineMyocardial infarctionhospital mortalitybiologybusiness.industryC-reactive proteinPercutaneous coronary interventionGeneral MedicineOdds ratioEmergency departmentmedicine.diseaseTroponinConfidence intervalmyocardial infarctionCardiologybiology.proteinbusinesscoronary artery diseaseJournal of Clinical Medicine
researchProduct

Possible Pathogenetic Relevance of Interleukin-1beta in "Destructive" Organ-specific Autoimmune Disease (Hashimoto's Thyroiditis)

1999

Thyroid follicular cells (TFC) abundantly express a variety of immunologically relevant surface molecules in Hashimoto's thyroiditis (HT), for example, MHC antigens and adhesion molecules such as ICAM-1. Cytokines produced by infiltrating type 1 helper and cytotoxic T cells are importantly involved in de novo expression or up-regulation of such molecules. We recently demonstrated that TFC from HT patients almost invariably bear on their surface two additive functional molecules: Fas/Apo1/CD95, an important participant in apoptosis, and B7.1, a member of a family of "co-stimulatory" molecules that are crucial for efficient antigen presentation. To date, 12 out of 14 surgical HT thyroid speci…

medicine.medical_specialtymedicine.medical_treatmentAntigen presentationThyroid Glandmedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyFas ligandAutoimmunityHistory and Philosophy of ScienceInternal medicinemedicineHumansCytotoxic T cellfas ReceptorChemistryGeneral NeuroscienceThyroiditis AutoimmuneInterleukinFas receptorMolecular biologyGraves DiseaseRecombinant ProteinsCytokineEndocrinologyApoptosisB7-1 AntigenCytokinesInterleukin-1Annals of the New York Academy of Sciences
researchProduct